Teradyne (TER) Is Considered a Good Investment by Brokers: Is That True?

05.12.25 15:30 Uhr

Werte in diesem Artikel
Aktien

166,18 EUR -1,00 EUR -0,60%

Indizes

6.896,8 PKT -9,0 PKT -0,13%

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Teradyne (TER) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Teradyne currently has an average brokerage recommendation (ABR) of 1.65, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.65 approximates between Strong Buy and Buy.Of the 17 recommendations that derive the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 70.6% and 5.9% of all recommendations.Brokerage Recommendation Trends for TERCheck price target & stock forecast for Teradyne here>>>While the ABR calls for buying Teradyne, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is TER Worth Investing In?Looking at the earnings estimate revisions for Teradyne, the Zacks Consensus Estimate for the current year has increased 1.4% over the past month to $3.51.Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Teradyne. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, the Buy-equivalent ABR for Teradyne may serve as a useful guide for investors.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teradyne, Inc. (TER): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Teradyne und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Teradyne

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teradyne

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teradyne Inc.

Wer­bung

Analysen zu Teradyne Inc.

DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
DatumRatingAnalyst
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
24.01.2018Teradyne BuyStifel, Nicolaus & Co., Inc.
05.07.2017Teradyne BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
21.11.2017Teradyne HoldDeutsche Bank AG
29.10.2015Teradyne Sector WeightPacific Crest Securities Inc.
11.06.2012Teradyne neutralUBS AG
DatumRatingAnalyst
30.07.2009Teradyne ErsteinschätzungMorgan Stanley
22.12.2008Teradyne underweightJP Morgan Chase & Co.
06.12.2005Update Teradyne Inc.: UnderperformGoldman Sachs
06.12.2005Teradyne underperformGoldman Sachs

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teradyne Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen